Related Experiment Video
Updated: Jul 12, 2025
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
Analysis of General Toxicity of Ergoferon
E A Danchenko1, I A Ertuzun1, L I Bugaeva2
1LLC "MATERIA MEDICA HOLDING", Moscow, Russia.
Antiviral drug Ergoferon, made with processed antibodies, showed no lethal outcomes or adverse effects in adult rats during acute and repeated dose toxicity studies. This suggests a favorable safety profile for this antibody-based therapy.
Area of Science:
- Pharmacology
- Immunology
- Toxicology
Background:
- Antibody-based drugs are crucial in therapy but their toxicity can limit use.
- Understanding the safety profile of novel antibody-based antivirals is essential.
Purpose of the Study:
- To evaluate the general toxicity of the antiviral drug Ergoferon.
- To assess acute and repeated dose toxicity in adult animals.
Main Methods:
- Acute toxicity testing in adult rats at maximum tolerated doses.
- Repeated dose toxicity studies in adult rats.
Main Results:
- No lethal outcomes were observed during acute toxicity testing.
- No adverse effects were detected in the repeated dose toxicity study.
Conclusions:
- Ergoferon demonstrates a lack of acute and repeated dose toxicity in adult rats.
- The drug exhibits a favorable safety profile, warranting further clinical investigation.
More Related Videos
08:16Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
08:56Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry
Published on: November 22, 2024
